Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
13.98
+0.99 (7.62%)
At close: Feb 6, 2026, 4:00 PM EST
13.93
-0.05 (-0.37%)
After-hours: Feb 6, 2026, 6:43 PM EST

Amylyx Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
1,5352579942,448--
Market Cap Growth
533.43%-74.11%-59.40%---
Enterprise Value
1,197266442,292--
Last Close Price
13.983.7814.7236.95--
PE Ratio
--20.17---
Forward PE
--16.68---
PS Ratio
-2308.692.952.61110.13--
PB Ratio
4.621.562.297.19--
P/TBV Ratio
4.621.562.297.19--
P/FCF Ratio
--93.08---
P/OCF Ratio
--83.39---
EV/Sales Ratio
-0.291.69103.12--
EV/EBITDA Ratio
--16.13---
EV/EBIT Ratio
--16.59---
EV/FCF Ratio
--60.27---
Debt / Equity Ratio
0.020.010.010.02-0.27
Debt / EBITDA Ratio
--0.10---
Debt / FCF Ratio
--0.40---
Asset Turnover
-0.250.840.090.010.08
Inventory Turnover
--6.39---
Quick Ratio
13.356.235.027.785.531.76
Current Ratio
13.706.675.668.206.031.86
Return on Equity (ROE)
-56.53%-100.88%12.73%-92.53%-188.05%-
Return on Assets (ROA)
-39.44%-51.31%5.34%-50.63%-86.34%-281.44%
Return on Invested Capital (ROIC)
--1032.25%106.30%---
Return on Capital Employed (ROCE)
-57.40%-176.70%8.90%-58.40%-93.70%-575.50%
Earnings Yield
-9.72%-117.25%4.96%-8.10%--
FCF Yield
-12.42%-79.27%1.07%-7.45%--
Buyback Yield / Dilution
-24.05%2.64%-19.65%-788.13%-8.37%-3.20%
Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q